Rates of serious adverse events , including heart failure ( @ % for aleglitazar vs @ % for placebo , P = @ ) , gastrointestinal hemorrhages ( @ % for aleglitazar vs @ % for placebo , P = @ ) , and renal dysfunction ( @ % for aleglitazar vs @ % for placebo , P < @ ) were increased .